Latest Hotspot

Disc Medicine Launches Phase 1 Trial of DISC-3405 with Healthy Participants

16 October 2023
3 min read

Disc Medicine, Inc., a biotech business in the clinical trial stage that's concentrating on identifying, creating, and marketing unique remedies for severe blood-related illnesses, has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

DISC-3405 is a specially made monoclonal antibody that aims to target TMPRSS6 (Transmembrane Serine Protease 6, or Matriptase-2) with the goal of boosting hepcidin and lowering iron levels.

“With the start of this trial, Disc successfully introduces its third clinical program, solidifying our standing in the area of hepcidin biology and iron equilibrium. We consider DISC-3405 to have wide-ranging applicability in various conditions where iron regulation could provide a medical advantage, such as polycythemia vera, iron surplus syndromes and numerous other disorders.” commented John Quisel, J.D., Ph.D., the President and CEO of Disc.

“Upon this trial's conclusion, we are eager to explore these applications. This significant step arrives at a thrilling period for our organization as we anticipate revealing data insights from the ongoing clinical assessments of our other two initiatives, bitopertin and DISC-0974, within the year.” Further, John Quisel expounded.

The scrutiny will pursue a randomized, double-masked, placebo-managed, single- and multiple-rising dose Phase 1 trial in healthy volunteers, aiming to assess safety, tolerability, pharmacokinetics, and indications of pharmacodynamic action, including indicators of iron equilibrium and erythropoiesis.  

The single-rising dose fragment of the analysis is projected to register four batches at escalating dosage quantities, commencing with intravenous administration with an approach to shift to subcutaneous administration later in the study. The multiple-rising dose fragment is foreseen to register two batches, each undergoing subcutaneous injections of DISC-3405. Upon the completion of this scrutiny, Disc projects to launch a trial in polycythemia vera, a condition for which DISC-3405 has been granted Fast Track Designation.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of October 14, 2023, there are 9 investigational drugs for the TMPRSS6 target, including 8 indications, 11 R&D institutions involved, with related clinical trials reaching 12and as many as 618 patents.

DISC-3405, formerly known as MWTX-003, is an investigational, anti-TMPRSS6 monoclonal antibody designed to increase hepcidin production and suppress serum iron, that Disc in-licensed from Mabwell Therapeutics in January 2023. Its Fast Track designation and progress in clinical development indicate that it is an area of interest in the pharmaceutical industry, with potential for addressing unmet medical needs in these therapeutic areas.

图形用户界面, 文本

描述已自动生成

What is Complete Response (CR) in Clinical Trials?
"What" Series
2 min read
What is Complete Response (CR) in Clinical Trials?
16 October 2023
Complete response (CR) is defined as the absence of detectable tumor in the patient's body. Radiology and histopathology are used to measure CR, serving as surrogate or primary endpoints depending on the specific disease or use scenario.
Read →
Kineta Reports Encouraging Findings for KVA12123 Monotherapy from Phase 1/2 Clinical Study
Latest Hotspot
3 min read
Kineta Reports Encouraging Findings for KVA12123 Monotherapy from Phase 1/2 Clinical Study
16 October 2023
Kineta, Inc., a clinical-stage biotech firm specializing in unique cancer immunotherapies, has shared updates on their ongoing Phase 1/2 clinical trial of KVA12123 for advanced solid tumor patients.
Read →
What is Duration of Response (DoR) in Clinical Trials?
"What" Series
2 min read
What is Duration of Response (DoR) in Clinical Trials?
16 October 2023
Duration of Response (DoR) is defined as the time from randomization to disease progression or death for patients who achieve complete or partial alleviation.
Read →
Analysis on the Research Progress of Oncolytic virus
Advanced Tech.
6 min read
Analysis on the Research Progress of Oncolytic virus
16 October 2023
Oncolytic virus (OVs) refers to a generic name for viruses that naturally exist or are genetically edited to selectively kill tumor cells.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.